Given concurrently with chemotherapy to premenopausal patients undergoing treatment for early-stage breast cancer, gonadotropin-releasing hormone agonists (GnRHa) may be used to increase rates of recovery of regular menses and prevent early menopause, according to meta-analysis of 1,047 patients. The study determined:
• The use of GnRHa was associated with a higher rate of recover of regular menses after 6 months (OR=2.41) and at least 12 months (OR=1.85) following the last chemotherapy cycle.
• The use of GnRHa was associated with a higher number of pregnancies (OR=1.85).
• Evidence was insufficient to assess outcomes related to GnRHa and ovarian function and fertility.
Citation: Munhoz RR, Pereira AA, Sasse AD, et al. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer. [Published online ahead of print October 1, 2015]. JAMA Oncol. doi: 10.1001/jamaoncol.2015.3251.
This Week's Must Reads
Must Reads in Breast Cancer
Gender Images & Social Expectations in BC Diagnosis, Cancer; ePub 2018 Sep 24; Kim, Glassgow, et al
Predicting Mammography Adherence by Income Level, Women’s Health Issues; ePub 2018 Aug 8; Gathirua-Mwangi, et al
Estrogen-alone Therapy & Invasive Breast Cancer, Menopause; ePub 2018 May 7; Shufelt, et al
Missed Breast Cancers in High Risk MRI Screening, Breast Cancer Res Treat; ePub 2018 Jan 31; Vreemann, et al